Asset
GALICAFTOR
Lakefront Biotherapeutics American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03540524 | phase1 | completed | 2018-05-31 | 2019-03-11 | Lakefront Biotherapeutics NV | A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. |
| NCT03128606 | phase1 | completed | 2017-03-28 | 2018-02-20 | Lakefront Biotherapeutics NV | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. |
| NCT03045523 | phase2 | completed | 2017-01-01 | 2017-08-11 | Lakefront Biotherapeutics NV | A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis |
| NCT03119649 | phase2 | completed | 2017-03-18 | 2017-10-19 | Lakefront Biotherapeutics NV | A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis |
FDA applications (0)
This company has no applications containing this asset.